MANAGEMENT OF ENDOMETRIOSIS WITH ORAL MEDROXYPROGESTERONE ACETATE

article OA: closed CC0 ⤵ 67 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-07

Oral medroxyprogesterone acetate (MPA) at 30 mg daily for 90 days improved or caused remission of endometriosis in all 35 women, with 12 of 26 infertile patients becoming pregnant.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Efficacy of oral medroxyprogesterone acetate (MPA) was assessed in 35 women with an established diagnosis of endometriosis (33 pelvic and 2 abdominal). MPA was given in a dosage of 30 mg daily for 90 days. Results indicated improvement or remission in all cases, even though breakthrough bleeding occurred in 8. Twenty-six were treated for associated infertility. Twelve of these became pregnant following treatment. Pregnancy rate in those women whose husbands were fertile was 90%. Side effects included spotting and breakthrough bleeding. The patients usually remained amenorrheic and anovulatory while receiving MPA. Posttreatment resumption of ovulation was prompt. The findings indicate that oral MPA is a useful therapeutic agent in the management of minimal to moderate endometriosis, particularly when it is associated with infertility.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisinfertility

MeSH descriptors

Abdominal Neoplasms Endometriosis Medroxyprogesterone Pelvic Neoplasms Abdominal Neoplasms Administration, Oral Endometriosis Female Humans Male Medroxyprogesterone Medroxyprogesterone Medroxyprogesterone Pelvic Neoplasms Pregnancy Progesterone Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T16:23:13.998983+00:00
pubmed
last seen: 2026-05-14T05:58:58.463083+00:00
License: CC0 · commercial use OK